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TGF-b1 induced FGF-2, which results in fibroblast prolifera-TGF-b1 induces proliferation in human renal fibroblasts via
tion, we hypothesized that TGF-b1 may cause fibroblast prolif-induction of basic fibroblast growth factor (FGF-2).
eration mediated by FGF-2. This hypothesis was verified byBackground. The prognosis of primary renal disease is often
cell proliferation assays demonstrating that stimulation of renaldependent on the degree of tubulointerstitial scarring. Scarring
fibroblasts with TGF-b1 resulted in an up to 3.21 6 0.28-foldis caused by proliferation and excessive matrix production of
increase in bromodeoxyuridine incorporation and a 1.95 6renal fibroblasts and possibly other cellular elements. Trans-
0.16-fold increase in cell number after 72 hours. This mitogenicforming growth factor-b (TGF-b) is the most important cyto-
effect of TGF-b1 could be blocked completely by the additionkine for the induction of matrix synthesis in the kidney. How-
of a neutralizing antibody to FGF-2 or the tyrosine kinaseever, its effects on renal fibroblast proliferation have not been
inhibitor tyrphostin AG1296, which blocks FGF receptordetermined. We have recently demonstrated that the expres-
(FGFR) tyrosine kinase activity. Conversely, a neutralizingsion of basic fibroblast growth factor (FGF-2) is robustly up-
antibody to epidermal growth factor (EGF) or the tyrphostinregulated in human kidneys with tubulointerstitial fibrosis and
B42, which inhibits EGF receptor signal transduction, had nothat FGF-2 is a potent inducer of fibroblast proliferation. The
effect. Interestingly, a neutralizing antibody to PDGF had onlypresent study examined the interaction between TGF-b1 and
minor effects in primary kidney fibroblasts but reduced TGF-FGF-2 in human renal fibroblasts.
b1–induced proliferation considerably in primary skin fibro-Methods. Experiments were performed on a transformed
blasts. Finally, TGF-b1–induced proliferation in kidney fibro-medullary fibroblast line and on primary cortical kidney and
blasts was paralleled by a robust increase in cdk 2 proteinskin fibroblasts isolated from human biopsies. mRNA levels
expression up to 72 hours, whereas p27kip1, whose activity isof FGF-2 and TGF-b1 were analyzed by Northern blot analy-
maintained by TGF-b in epithelial cells, was down-regulatedses. Changes in protein expression were examined by immu-
up to 48 hours.noblots and enzyme-linked immunosorbent assay (ELISA).
Conclusions. Our studies demonstrate, to our knowlege forBromodeoxyuridine incorporation assays and cell counts were
the first time, that TGF-b1 induces proliferation in humanused to analyze cell proliferation. The expression of cell cycle-
renal fibroblasts and that this process is mediated largely byregulatory proteins cyclin-dependent kinase (cdk) 2 and the
FGF-2. The induction of proliferation by TGF-b1 via inductioncdk inhibitor p27kip1 were determined by immunoblots.
of FGF-2 may play an important role in the autonomy ofResults. Stimulation of renal fibroblasts with FGF-2 resulted
renal fibroblast growth and thus in the pathogenesis of humanin no change of TGF-b1 mRNA expression, whereas incuba-
fibrogenesis.tion of the cells with TGF-b1 induced FGF-2 mRNA up to
3.51 6 0.21-fold after six hours. This increase could be blocked
almost completely by the addition of cyclohexamide, indicating
that the process is in large part dependent on protein synthesis. Interstitial fibrosis invariably accompanies the course
The up-regulation in FGF-2 mRNA expression was paralleled of chronic renal failure toward end-stage renal diseaseby de novo detection of FGF-2 protein in the supernatant,
[1]. A great number of studies have demonstrated thatpeaking after 12 to 24 hours, as determined by Western blot
interstitial scarring is an accurate predictor of renal func-and ELISA, whereas cellular protein was only increased up to
2.1-fold. Interestingly, both methods detected release of FGF-2 tion in primary glomerular diseases, diabetic nephropa-
protein to the supernatant already at three hours, indicating a thy, hypertensive nephropathy, polycystic kidney disease,
role for TGF-b1 in directly releasing preformed FGF-2. Since and chronic pyelonephritis [reviewed in 2]. Cytokines
play an important role in the pathogenesis of renal fibro-
genesis, including platelet-derived growth factor (PDGF)Key words: kidney fibrosis, extracellular matrix, epidermal growth fac-
tor, platelet-derived growth factor, cdk 2, p27kip1, human fibrogenesis. and transforming growth factor-b (TGF-b). PDGF is
a strong inducer of proliferation in some but not allReceived for publication December 30, 1999
fibroblasts [3]. TGF-b is probably the most importantand in revised form August 15, 2000
Accepted for publication August 30, 2000 cytokine for the accumulation of matrix in renal fibro-
genesis [4]. It induces the formation of interstitial matrixÓ 2001 by the International Society of Nephrology
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proteins, including collagen types I and III, as well as fi- in the release of preformed FGF-2. Furthermore, we
show that TGF-b1 promotes proliferation in medullarybronectin. Furthermore, it induces the expression of the
plasmin activator inhibitor-1, thus delaying matrix degra- and cortical fibroblasts and that this effect is mediated
mainly by induction of FGF-2. Finally, we demonstratedation [5]. TGF-b1 expression was found to be elevated
in several animal models of chronic progressive renal dis- that TGF-b1–induced proliferation is characterized by
increased synthesis of cyclin-dependent kinase (cdk) 2ease associated with interstitial fibrosis, including Hey-
mann nephritis [6], antiglomerular basement membrane and a decrease in p27kip1 synthesis up to 48 hours.
disease [7], purine aminonucleoside nephrosis [6], hyper-
tensive [8] and obstructive nephropathy [9], chronic re-
METHODS
jection [10], as well as most recently in a model of fibrosis
Materialsfollowing papillary necrosis [11]. Furthermore, mice ex-
pressing the TGF-b1 transgene in the liver under control Human recombinant FGF-2 and TGF-b1 were pur-
chased from R&D Systems (Minneapolis, MN, USA),of the murine albumin promoter developed glomerulo-
sclerosis and tubulointerstitial fibrosis [12]. Thus, TGF-b as were the neutralizing antibodies to epidermal growth
factor (EGF; goat polyclonal), FGF-2 (goat polyclonal),has been proposed as a potential target for gene therapy
to prevent the progression of chronic renal disease [13]. PDGF (rabbit polyclonal), and TGF-b (chicken poly-
clonal). Rabbit polyclonal antibody to FGF-2 (Ab-2) wasThe role of other cytokines in renal fibrogenesis is less
well defined. One potential candidate for an important obtained from Calbiochem (La Jolla, CA, USA). The
following mouse monoclonal antibodies were used for cellrole in the pathogenesis of kidney fibrosis is basic fibro-
blast growth factor (FGF-2). FGF-2 is a single-chain characterization: anticollagen type I, anticollagen type III
(both from Southern Biothechnology, Birmingham, AL,polypeptide with a molecular weight of 18 kD, which
binds to four high-affinity receptors [FGF receptor-1 USA), anticytokeratin (Dako, Carpinteria, CA, USA),
antivimentin (Boehringer Mannheim, Mannheim, Ger-(FGFR-1) to FGFR-4]. These FGFRs function as protein
tyrosine kinases and regulate a wide variety of cellular many), antifactor VIII (Dako), anti–HLA-DR (Dako),
anti–a-smooth muscle actin (Paesel1Lorei, Wiesbaden,processes [reviewed in 14]. FGF-2 has been implicated
in the pathogenesis of skin, liver, and lung fibrosis. Char- Germany), anti-CD 44 (Pharmingen, San Diego, CA,
USA), and anti-CD 54 and anti-CD 68 (Dako). Thelotte et al, for example, found increased expression of
FGF-2 in carbon tetrachloride-induced liver fibrosis [15]. mouse monoclonal antibody to collagen type IV was a
generous gift from Steven Gay (University of Zu¨rich,In the kidney, FGF-2 is a potent mitogen for proximal
tubular epithelial and mesangial cells [16, 17]. Further- Zu¨rich, Switzerland). FGF-2 and TGF-b1–specific oligo-
nucleotides were purchased from R&D Systems, andmore, subcutaneous injections into rats for 8 and 13
weeks caused focal segmental glomerulosclerosis and tyrphostines AG1296 and B42 were from Calbiochem-
Novabiochem (Nottingham, UK). Rabbit polyclonalwidening of the peritubular interstitium [18]. Finally, in a
transgenic mouse model of HIV nephropathy, interstitial anti-cdk 2 antibody was also obtained from Calbiochem-
Novabiochem. The anti-p27kip1 antibody was from Trans-FGF-2 staining was increased and colocalized with extra-
cellular matrix [19]. Fibroblasts are the main effector duction Laboratories (Lexington, KY, USA). Ham’s
F-12 medium was from Seromed Biochem. KD, Berlin,cells in human renal fibrogenesis, although other cells
may play a role as well as was demonstrated by us and Germany. Bovine collagen, insulin, transferrin, sele-
nium, hydrocortisone, and tri-iodothyronine were pur-other groups [20, 21]. Recently, we have shown that
FGF-2 protein and mRNA expression are increased in chased from Sigma (St. Louis, MO, USA). Trypsin-
ethylenediaminetetraacetic acid [0.05/0.02% (wt/vol)],human kidneys with tubulointerstitial fibrosis and that
the degree of fibrosis correlates well with staining for Dulbecco’s modified Eagle’s medium (DMEM), Iscove’s
modified Dulbecco’s medium, and fetal calf serum (FCS)FGF-2 [22]. Moreover, we have shown that FGF-2 is a
potent mitogen for human cortical fibroblasts and that were obtained from GIBCO BRL Ltd. (Paisley, Scot-
land). Cell culture dishes were from Becton Dickinsonthese cells express the FGFR-1 as well as low-affinity
receptors (heparan sulfate proteoglycans). Since a neu- (Franklin Lakes, NJ, USA).
tralizing antibody to FGF-2 was capable of inhibiting
Cell culturebasal fibroblast proliferation, we concluded that FGF-2
may mediate autocrine fibroblast proliferation. Cortical fibroblasts and tubular epithelial cells were
cultured from biopsies after patients had given their con-Thus, the aim of the present study was to analyze the
interaction between FGF-2 as a mediator of fibroblast sent to a second biopsy for research purposes. Skin fi-
broblasts were also established from skin biopsies at theproliferation and TGF-b1 as an inducer of extracellular
matrix synthesis in human renal fibroblasts in vitro. We time of kidney biopsy as controls. The use of parts of
kidney and skin biopsies for research purposes was ap-demonstrate that TGF-b1 induces FGF-2 synthesis on
the mRNA and protein levels robustly, which may result proved by the Ethics Committee of the Georg-August-
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University. Written consent was obtained from all pa- modifications [20]. Briefly, 40 mg of total RNA were
electrophoresed on a 1.0% agarose gel containingtients prior to kidney and skin biopsy. Biopsies were
performed according to standard procedures using the 2.2 mol/L formaldehyde. One 3 MOPS, pH 7.0, was
used as the running buffer. Ethidium bromide-stainedBiopty gun with a 18-gauge needle under real-time ultra-
sound guidance. For isolation of primary human kidney gels were subsequently photographed under ultraviolet
illumination, and RNA was transferred to a nylon mem-fibroblasts, cortical parts of renal biopsy cylinders were
cut and emerged in DMEM medium supplemented with brane (Hybond N; Amersham, Arlington Heights, IL,
USA) by capillary transfer overnight. Blots were than20% FCS, penicillin (100 U/mL), and streptomycin (100
U/mL). When cells had grown to confluency, cells were baked at 808C for two hours and prehybridized for one
hour at 688C in prehybridization solution containingsplit 1:1 and were characterized by immunofluorescence
for cytokeratin, vimentin, a-smooth muscle actin, colla- 0.5 mol/L Na2HPO4 buffer (pH 7.2), 0.5 mol/L ethylene-
diaminetetraacetic acid (EDTA; pH 8), 25% sodium do-gen types I, III, and IV, factor VIII, CD 44, CD 54, CD
68, and HLA-DR. Cells that were positive for vimentin, decyl sulfate (SDS), and 1.5% blocking reagent. RNA
from TGF-b1–stimulated cells was then hybridized withCD 44, CD 54, a-smooth muscle actin, and the collagen
types I and III and negative for cytokeratin, factor VIII, FGF-2–specific oligonucleotides, RNA from FGF-2–
stimulated cells with TGF-b1 specific oligonucleotides.and HLA-class II were considered to be fibroblasts and
used for induction assays in passages 2 through 8. In se- Oligonucleotides had been labeled with digoxigenin ac-
cording to instructions from Boehringer Mannheim. Hy-lected stainings, additional staining with the Hoechst dye
H33258 was performed to facilitate cell counting. For bridizations were performed for 12 hours at 588C. After
washing, anti-DIG alkaline phosphatase and CSPD sub-quantitation of expression of a-smooth muscle actin, cyto-
keratin, and collagen types I and III, 400 cells were strate (both Boehringer Mannheim) were added. Posi-
tive reaction products were identified by chemilumines-counted, and the relative percentage of positive cells was
determined. cence using a Fluor-Se Multiimager (Bio-Rad, Hercules,
CA, USA), and densitometric analysis was performedPrimary human proximal tubular epithelial cells
(PTECs) were cultured according to the method by De- using Multi-Analyste software (Bio-Rad). All blots
were stripped and hybridized with digoxigenin labeledtrisac et al and characterized as described previously
[23, 24]. PTECs were grown on a matrix of bovine colla- 18S-RNA (Ambion, Austin, TX, USA) as control. Data
from five different blots with RNA from independentgen and heat-inactivated FCS and cultured in serum-
free DMEM and Ham’s F-12 medium in a 1:1 ratio sup- experiments were summarized and are given after cor-
rection for 18S-RNA density.plemented with insulin (5 mg/mL), transferrin (5 mg/mL),
selenium (5 mg/mL), hydrocortisone (36 ng/mL), tri- For further investigation of the mechanisms of TGF-b1–
induced FGF-2 mRNA synthesis, experiments were re-iodothyronine (40 pg/mL), and EGF (10 ng/mL). Cells
were used in passages 3 through 6. peated in the presence of cyclohexamide (1 mg/mL) to
inhibit translation. These experiments were repeatedEpithelial skin biopsies, obtained at the time of renal
biopsy from the puncture site, were treated as described three times, and results are given corrected for 18S-RNA
density. Toxicity of cyclohexamide was evaluated by lac-previously for cortical fibroblast culture. Skin fibroblasts
were characterized as described for kidney fibroblasts tic acid dehydrogenase (LDH) measurements in super-
natants by routine procedures.and used in passages 2 through 8. Human renal medullary
fibroblast cell lines Tk 173 (obtained from a normal kid-
Protein measurementsney) and Tk 188 (from a kidney with tubulointerstitial
fibrosis) have been characterized previously [25] and Protein synthesis of FGF-2 after induction by TGF-b1
was analyzed by immunoblot analysis and enzyme-linkedwere cultured in DMEM supplemented with 10% FCS,
penicillin, and streptomycin (100 U/mL each). immunosorbent assay (ELISA). Tk 173 cells were plated
at a density of 6000 per well and were serum deprived
mRNA analyses over 24 hours by culture in Iscove’s medium. Subse-
quently, cells were stimulated with 1 ng/mL TGF-b forTo analyze possible interactions between FGF-2 and
TGF-b1, cells were rested for 24 hours in Iscove’s me- 0, 3, 6, 12, 24, and 48 hours without additional additives.
Lysates were obtained with a detergent-based bufferdium prior to stimulation with FGF-2 (1 ng/mL) or
TGF-b1 (1 ng/mL). After 0, 3, 6, 9, 12, and 24 hours, containing 0.4% sodium deoxycholate, 1% NP-40, 1.9%
EGTA, and 10 mmol/L Tris (pH 7.4); 100 mg of totaltotal cellular RNA was extracted using RNA-cleane
(AGS, Heidelberg, Germany) according to instructions cellular protein were run on an 15% SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) gel and trans-available from the manufacturer with minor modifica-
tions. RNA concentrations were determined at 260 nm, ferred to a nitrocellulose membrane (Hybonde ECLe;
Amersham). Supernatants were concentrated 310 andand samples were stored at 2808C prior to use. Northern
blot analysis was performed as described previously with loaded after correction for cell number. Membranes
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were subsequently stained with Ponceau red to control ization of the stimulation of collagen type I secretion by
TGF-b1 (10 ng/mL) in Tk 188 cells. Medium was changedfor adequate transfer and equally loaded amounts,
blocked with a phosphate-buffered saline (PBS) solution to Iscove’s containing bromodeoxyuridine/FdU in a dilu-
tion of 1:500 four hours prior to measurements. Cellscontaining 0.2% Tween 20 and 5% dry milk and incu-
bated with an anti–FGF-2 antibody at a concentration were then washed three times in PBS and fixed in metha-
nol containing 2% hydrogen peroxide followed by dena-of 1:40. After several washes, and incubation with the
secondary antibody (donkey-anti-rabbit, horseradish per- turation in 1N HCl for 10 minutes. After further washing
for three times in PBS containing 0.1% Tween andoxidase linked; Amersham) ECL-Plus (Amersham) was
added according to the manufacturer’s protocol to iden- blocking for 30 minutes in PBS (0.1% Tween, 3% bovine
serum albumin), 50 mL of anti-bromodeoxyuridine anti-tify positive reaction products by chemiluminescence
using the Fluor-Se Multiimager. Western blots were inde- body were added and incubated for 45 minutes. Cells
were again washed three times in PBS/Tween, and perox-pendently performed three times from independent ex-
perimental series with qualitatively similar results. Densi- idase substrate was added (100 mL/well). Optical densi-
ties were subsequently determined photometrically attometric analyses were carried out using Multi-Analyste
software, and data of all series were summarized. 405 nm (Dynatech MR 4000, Denkendorf, Germany).
In a second set of experiments, confluent monolayersFibroblast growth factor-2 protein secretion was quan-
titated by commercial ELISA (Qantikine immunoassay of Tk 173 and Tk 455 kidney fibroblasts were trypsinized,
and cells were seeded at 4 3 103 cells/well in 96-wellhuman bFGF; R&D Systems, DFB 50) in parallel experi-
ments according to instructions available from the manu- culture plates. After 12 hours of incubation, DMEM
medium was replaced by Iscove’s medium. After an addi-facturer. This assay has a sensitivity of 3 pg/mL with a
working range of 10 to 640 pg/mL. There is no known tional 24 hours, cells were stimulated with three different
concentrations of TGF-b1 (0.1, 1.0, and 10 ng/mL).cross-reactivity to other cytokines and growth factors.
Cells were plated and prepared as detailed. Subse- FGF-2 at a concentration of 10 ng/mL served as positive
control, and Iscove’s medium alone served as the nega-quently, cells were stimulated with 1 ng/mL TGF-b for
0, 3, 6, 12, 24, and 48 hours. Cells were counted after tive control. Anti–TGF-b1 and anti–FGF-2 were added
to selected wells in the previously mentioned concen-supernatants had been removed to account for TGF-b1–
induced proliferation, and FGF-2 measurements were trations. In addition, the effect of an irrelevant IgG (anti–
HLA-DR) was examined in a concentration of 10 mg/mL.corrected for cell number. Results are given in pg per
mL per 1000 cells. Cells were counted after 72 hours using a Neubauer
chamber.
Proliferation assays The effect of the tyrosine kinase inhibitors tyrphostin
AG1296, which inhibits the FGF-receptor tyrosine ki-Proliferation studies were performed using bromo-
deoxyuridine incorporation assays and cell counts. In a nase, and tyrphostin B42 (AG 490), which blocks the
EGF receptor kinase, was then analyzed in a similarfirst set of experiments, Tk 173 and Tk 455 were plated
at 4 3 103 cells per well in 96-well microtiter plates experimental setting. The dose of the tyrphostines was
determined in experiments neutralizing the proliferativecontaining DMEM medium with FCS and incubated
overnight. Cells were then made quiescent by replace- effects of FGF-2 (1 ng/mL) on Tk 173 fibroblasts and of
EGF (1 ng/mL) in PTECs. Tk 173 and Tk 455 kidneyment of DMEM with Iscove’s medium and subsequent
incubation for 24 hours. TGF-b1 was added thereafter fibroblasts were again plated at 4 3 103 cells per well.
TGF-b1 was added at a concentration of 1 ng/mL afterin a concentration of 1.0 ng/mL, and proliferation was
measured after 24, 48, 72, and 96 hours by nonradioactive 24 hours of incubation in Iscove’s medium. In addition
to TGF-b, neutralizing antibodies to TGF-b or FGF-2bromodeoxyuridine incorporation assays (Amersham)
based on the method by Gratzner et al [26]. Assays were were added (both at concentrations of 10 mg/mL) as
well as the tyrphostines AG 1296 (at a concentration ofperformed according to the manufacturer’s instructions
with some modifications. Iscove’s medium without addi- 5 mmol/L) and B42 (concentration 500 nmol/L). Iscove’s
alone served as negative control. Cells were countedtives served as the negative, and FGF-2 in a concentra-
tion of 10 ng/mL served as the positive control. Neutraliz- after 24, 48, 72, and 96 hours. In control experiments,
the effects of both tyrphostines on FGF-2–induced pro-ing antibodies to TGF-b1, FGF-2, or EGF were added to
selected cells stimulated with TGF-b1. The appropriate liferation of both fibroblast lines after 72 hours were
assayed. Serial LDH measurements were obtained byconcentrations of the neutralizing antibodies (10 mg/mL
for anti-FGF-2, 10 mg/mL for anti-EGF, 10 mg/mL for standard procedures from supernatants containing the
tyrphostines to exclude toxic effects.anti-PDGF, and 1 mg/mL for anti–TGF-b1) were identi-
fied in control experiments neutralizing the proliferative In a final set of proliferation experiments, primary
cortical fibroblasts Tk 458, Tk 469, and primary skineffects of EGF (1 ng/mL) on PTECs, FGF-2 (1 ng/mL)
and PDGF (1 ng/mL) on Tk 173 fibroblasts, or neutral- fibroblasts Sk 448 and Sk 449 were plated at a density
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of 4 3 103 cells per well. All cells were made quiescent
by incubation in Iscove’s medium without additives for
24 hours and subsequently stimulated with TGF-b1 at
1 ng/mL. In selected wells, neutralizing antibodies to
TGF-b1 (10 mg/mL), FGF-2 (10 mg/mL), PDGF (10 mg/
mL), or EGF (5 mg/mL) were added, and bromodeoxyur-
idine incorporation was determined after 72 hours. All
proliferation assays were performed in triplicate and re-
peated four times.
Immunoblot analyses for cell cycle proteins
Western blot analyses were performed as described
previously in this article with minor modifications. Tk
173 and Tk 455 fibroblasts were incubated with 1 ng/mL
TGF-b1, and lysates were obtained after 0, 24, 48, and
72 hours. Again, 100 mg of protein were run on an 18%
SDS-PAGE gel, and membranes were stained with Pon-
ceau red after transfer. Anti-cdk 2 antibody was used in
a concentration of 1:500, and anti-p27kip1 antibody was
used in a concentration of 1:2500. Donkey-anti-rabbit Fig. 1. Characterization of primary cortical fibroblasts by immunoflu-
and goat-anti-mouse horseradish peroxidase-linked anti- orescence. Primary cortical fibroblast line Tk 455 stained positively for
vimentin (A), collagen type I (C), collagen type III (E), and a-smoothbodies (Amersham) were used as the secondary antibod-
muscle actin (F ). No staining was observed for cytokeratin (B) andies. Positive reaction products were identified by chemi- factor VIII (D). Costainings with the Hoechst dye H33258 identifying
luminescence as described previously in this article. cell nuclei were performed.
Quantitative analyses were again obtained using Multi-
Analyste software. In control experiments, cells were
stimulated for 0, 24, 48, and 72 hours with TGF-b1
I was 96% in Tk 455 cells, 95% in Tk 458, and 96%(1 ng/mL) in the presence of the FGF-2–neutralizing
in Tk 469 fibroblasts. Regarding collagen type III, theantibody (10 mg/mL). Immunoblot analyses were per-
percentages were 94, 92, and 95%, respectively. The per-formed twice with qualitatively similar results.
centage of a-smooth muscle actin–positive cells was 88%
Statistical analyses in Tk 455, 78% in Tk 458, and 83% in Tk 469 fibroblasts.
All values are expressed as mean 6 SEM. One-way All three cell lines were negative for HLA-DR, factor
analysis of variance (ANOVA) was used to determine sta- VIII, and CD68. Figure 1 demonstrates the staining pat-
tistical differences between growth factor treated groups terns observed by indirect immunofluorescence labeling
and controls using Sigma-State software 2.03 (Jandel Sci- for vimentin, cytokeratin, factor VIII, collagen types I
entific, San Rafael, CA, USA). Further analysis was car- and III, and a-smooth muscle actin in Tk 455 fibroblasts.
ried out using Bonferroni’s method to control for multiple Primary skin fibroblast lines Sk 448 and Sk 449 were ob-
testing. P values #0.05 were considered significant. tained from a 57-year-old male with IgA nephropathy
and a 30-year-old male with membranous glomerulone-
phritis, respectively. All cells were negative for cytokera-RESULTS
tin and positive for vimentin and collagens type I and III.Characterization of primary cortical fibroblasts
Primary fibroblast line Tk 455 was established from TGF-b1 induces FGF-2 mRNA and protein synthesis
the biopsy of a 29-year-old female (C.M.) with IgA ne-
To study the interactions between FGF-2 and TGF-b1phropathy and tubulointerstitial fibrosis involving 25%
in human kidney fibroblasts, possible changes in cytokineof the interstitium. Tk 458 originated from the biopsy
expression were first studied by Northern blot analyses.of a 48-year-old male (B.G.) with diabetic nephropathy
The basal level of TGF-b1 mRNA expression in Tk 173and minimal (,10%) interstitial involvement, and Tk
and Tk 455 fibroblasts was very low, and stimulation469 was cultured from the biopsy of a 39-year-old female
with 0.1, 1.0, or 10 ng/mL FGF-2 did not result in any(S.M.) with marked interstitial fibrosis. After the second
change in expression level for TGF-b1 mRNA (data notpassage, the percentage of cytokeratin positive cells was
shown). Conversely, stimulation of both fibroblast linesless than 5% in each culture. All cells were positive for
with 1.0 ng TGF-b/mL caused an increase in FGF-2vimentin, CD44, and CD54 by indirect immunofluores-
cence. The percentage of positive cells for collagen type mRNA as early as three hours (175.6 6 23.7) after initia-
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Fig. 3. Detection of FGF-2 protein in the supernatant by immunoblot
(A) and ELISA (B). Cells were stimulated with 1 ng/mL TGF-b1 for
0, 3, 6, 12, 24, and 48 hours. Protein of supernatant was corrected for
cell number. (A) A characteristic immunoblot illustrating the robust
increase in FGF-2 protein in the supernatant peaking after 24 hours.
The de novo detection of the protein after only three hours of stimula-
tion points to a role of TGF-b1 in release of preformed FGF-2. (B)
Fig. 2. FGF-2 mRNA levels in Tk 173 fibroblasts after stimulation with A summary of ELISAs for FGF-2 in the supernatant confirming the
TGF-b1 (1 ng/mL) for 0, 3, 6, 9, 12, and 24 hours. (A) One representative immunoblot data. Protein values were corrected for cell number. *P ,
Northern blot with a main band at 7.0 kb 18S-RNA was used as internal 0.05; **P , 0.01 vs. control (5 0 hour).
control. (B) The densitometric analyses after five different stimulations
( ) and mRNA changes after the addition of cyclohexamide (j). *P ,
0.05; **P , 0.01 vs. control (5 0 hour).
tion, immunoblots for intracellular and secreted FGF-2
as well as ELISAs for FGF-2 in the supernatant were
tion of stimulation (Fig. 2). In Tk 173 fibroblasts, induc- performed in Tk 173 fibroblasts. Immunoblot analysis
tion peaked after six hours (350.9 6 21.2% compared demonstrated one main band at 18 kD. The relative
with basal level, P , 0.001) and was still robustly elevated amount of intracellular FGF-2 protein increased at maxi-
after 9 hours (261.6 6 20.7%, P 5 0.048) before returning mum by a factor of 2.1 6 0.23 (P , 0.05) after 24 hours
to its basal level after 12 and 24 hours. Figure 2B summa- (data not shown). Conversely, there was a robust in-
rizes the findings of five independent experiments in Tk crease in FGF-2 protein in the supernatant. This increase
173 fibroblasts. This increase could be almost completely peaked after 12 to 24 hours of incubation with TGF-b1
blocked by addition of cyclohexamide in a concentration (Fig. 3A). Furthermore, the increase in FGF-2 protein
of 1 mg/mL (maximum increase to 153.7 6 6.3% after in the supernatant was confirmed by ELISA. There was
9 h, P 5 0.096), indicating that protein synthesis is re- an increase from 1.4 6 1.4 ng/mL/4000 cells at 0 hours
quired for induction of FGF-2. In these experiments, to a maximum 43.3 6 10.8 ng/mL/4000 cells at 24 hours
toxic effects were excluded by serial measurements of (P 5 0.003; Fig. 3B). Thus, increased mRNA values
LDH, which did not change. Similar increases in FGF-2 are paralleled by increased values for intracellular and
mRNA were obtained in Tk 455 fibroblasts, although particularly secreted FGF-2 protein. Additionally, the
absolute values were somewhat lower (maximum in- detection of FGF-2 protein in the supernatant after only
three hours of incubation with TGF-b1 implies thatcrease to 245 6 18.9% after 9 h, P 5 0.035). Again,
induction of FGF-2 was almost completely prevented by TGF-b1 may result in the release of preformed FGF-2.
A similar mechanism has recently been proposed forcyclohexamide.
To assess whether this increase in FGF-2 mRNA syn- the release of TGF-b1 from tubular epithelial cells after
stimulation with FGF-2 [27].thesis was paralleled by a rise in FGF-2 protein produc-
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Fig. 4. TGF-b1–induced proliferation as de-
termined by bromodeoxyuridine incorpora-
tion in human kidney fibroblasts. (A) The time
dependency of TGF-b1–induced proliferation
in Tk 173 fibroblasts after stimulation with
TGF-b1 at 1 ng/mL. Cells grown in Iscove’s
medium without additives were used as con-
trols (5 100%). (B) The time dependency in
Tk 455 cells. The addition of a neutralizing
antibody to TGF-b (gray columns) and to
FGF-2 (dark gray columns) prevented the
TGF-b1–induced proliferation, whereas a neu-
tralizing antibody to EGF (light gray columns)
had no effect. *P , 0.05 vs. control; **P ,
0.01 vs. control.
TGF-b1 induces proliferation in human kidney poration, which peaked in both cell lines after 72 hours
fibroblasts in time- and dose-dependent fashion (bromodeoxyuridine incorporation 321 6 28.9% in Tk
173 fibroblasts and 210.9 6 12.3% in Tk 455 fibroblasts).Since TGF-b1–induced FGF-2 and FGF-2 is a strong
This increase could be inhibited by addition of neutraliz-mitogen for renal fibroblasts, we speculated that TGF-b1
ing antibodies to TGF-b1 and to FGF-2. Conversely,may induce proliferation in these cells. Figure 4 demon-
the addition of a neutralizing antibody to EGF had nostrates the results obtained in Tk 173 (Fig. 4A) and Tk
significant effect. FGF-2 (10 ng/mL) alone was used as455 (Fig. 4B) fibroblasts after stimulation with TGF-b1
the positive control and increased bromodeoxyuridine(1 ng/mL) for 24, 48, 72, and 96 hours. TGF-b1 induced
a time-dependent increase in bromodeoxyuridine incor- uptake to 375.9 6 28.7% of controls in Tk 173 and to
Strutz et al: TGF-b1 and human kidney fibroblasts586
285.3 6 24.1% in Tk 455 cells (data not shown). Next, neous, we determined the effects of TGF-b1 on skin
we analyzed the dose dependency of TGF-b1–induced fibroblasts. As depicted in Figure 7, TGF-b1 (1 ng/mL)
stimulation. Although all three doses tested induced cell induced a robust increase in bromodeoxyuridine incor-
proliferation in both fibroblast lines, 1.0 ng/mL had the poration in the two primary kidney [217.2 6 22.2% in
most robust effect (increases to 195.5 6 16.6% of controls Tk 458 and 295.0 6 17.5% in Tk 469 fibroblasts compared
in Tk 173 and by 161.8 6 17.2% in Tk 455 cells after with controls (5 100%)] and in the two skin (234.5 6
72 h), as shown in Figure 5, indicating that higher doses 12.6% in Sk 448 and 275.6 6 8.9% in Sk 449 cells) fibro-
may have additional antiproliferative effects. Again, blast lines after 72 hours. Thus, the mitogenic response
neutralizing antibodies to TGF-b1 and FGF-2 prevented was even more pronounced in the fibroblasts derived
the increase in cell number, whereas an irrelevant IgG from a kidney with little interstitial involvement. Again,
had no effect (Fig. 5). Cell counts for stimulation with
specificity of the effect was determined by addition of
FGF-2 were increased to 278.3 6 25.6% and to 214.5 6
a neutralizing antibody to TGF-b1, and a neutralizing17.8%, respectively (data not shown). At the same time
antibody to EGF had no effect on TGF-b1–induced in-these experiments demonstrated that bromodeoxyuri-
crease in uptake of bromodeoxyuridine. However, whereasdine incorporation was paralleled by increases in abso-
the neutralizing antibody to FGF-2 almost completelylute cell number. However, examining the time course
abolished the response to TGF-b1 in the two corticalof cell counts determined that the peak in proliferation
fibroblast lines (reduction to 93.2 6 12.3 and to 112.0 6after induction by TGF-b1 (1 ng/mL) was after 96 hours
15.6%), there was only partial inhibition in the two skin(increases in cell number by 205.9 6 23.4% in Tk 173
fibroblast lines (reduction to 156.7 6 8.9 and 164.5 6and by 171.5 6 17.4% in Tk 455 fibroblasts), although
the additional increase after 72 hours was only minimal. 15.1%). Interestingly, the addition of a neutralizing anti-
Thus, as expected, the peak in cell counts was later than body to PDGF caused only slight decreases in TGF-
the peak in bromodeoxyuridine incorporation. Absolute b1–induced proliferation in the kidney fibroblast lines
values were much higher in transformed Tk 173 fibro- but reduced bromodeoxyuridine uptake considerably in
blasts than in primary Tk 455 fibroblasts because of a Sk 448 and 449 (to 130.9 6 14.3 and 143.6 6 12.7% of
higher rate of basal proliferation. controls; Fig. 7). Thus, whereas PDGF may play only a
minor role in TGF-b1–induced proliferation in kidneyNeutralization of FGF receptor kinase inhibits
fibroblasts, it may have a more important function inTGF-b1–induced proliferation in renal fibroblasts
skin fibroblasts.
To analyze further the role of FGF-2 in TGF-b1–
induced fibroblast proliferation, we used two different TGF-b1 stimulation of kidney fibroblasts results in
tyrphostines (AG compounds). Tyrphostines inhibit ty-
up-regulation of cdk 2 and down-regulation of p27kip1rosine kinases by binding to the substrate binding site.
To elucidate further the effects of TGF-b1 on cellTyrphostines AG1296, which blocks FGF-2 receptor ty-
proliferation in human kidney fibroblasts, we analyzedrosine kinase activity, and B42 (AG 490), which inhibits
the effects on expression of cdk 2 and p27kip1 by immu-specifically EGF receptor kinase autophosphorylation,
were used. The results are depicted in Figure 6. The addi- noblot analyses. The results are shown in Figure 8. Ex-
tion of tyrphostin AG1296 blocked TGF-b1–induced pro- pression of cdk 2 was robustly up-regulated by TGF-b1
liferation completely in both fibroblast lines. Conversely, (1 ng/mL) in a time-dependent fashion in both cell lines
tyrphostin B42 had no significant effect, indicating that (Fig. 8A). As expected, basal cdk 2 expression was much
EGF does not play a role in the process of TGF-b1– higher in transformed Tk 173 cells than in primary Tk
induced fibroblast proliferation. At the concentration 455 fibroblasts. Still, a similar increase could be observed
used, AG1296 completely prevented the induction of in both cells up to 72 hours. Conversely, the expression
proliferation by FGF-2 alone in Tk 173 and Tk 455 fi- of p27kip1, which inhibits proliferation, was down-regu-
broblasts, whereas again, B42 had no significant effects lated up to 48 hours time dependently (Fig. 8B). How-
(data not shown). Measurements of LDH demonstrated
ever, after 72 hours of incubation with TGF-b1, levels ofthat there was no difference between supernatants from
p27kip1 returned back to basal levels, possibly explainingcells with and without tyrphostines excluding toxic ef-
why TGF-b1 induced proliferation decreases thereafter.fects at the applied doses (data not shown).
Interestingly, in contrast to cdk 2, basal levels of p27kip1
Neutralization of PDGF inhibits TGF-b1–mediated were not significantly different in the two cell lines. In con-
cell proliferation in skin but not in kidney fibroblasts trol experiments in the presence of a neutralizing antibody
to FGF-2, no significant changes in cdk 2 or p27kip1 wereWe next analyzed the effects of TGF-b1 on two addi-
observed (data not shown), adding additional proof thattional cortical primary fibroblasts (Tk 458 and 469). Fur-
thermore, since fibroblasts are known to be heteroge- the mitogenic effects of TGF-b1 are mediated via FGF-2.
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Fig. 5. Partial dose dependency of TGF-b1–
induced proliferation in Tk 173 (A) and Tk
455 (B) fibroblasts, indicating a maximal pro-
mitogenic effect of 1 ng/mL. Cells were origi-
nally plated at a density of 4000 per well and
stimulated with 0.1, 1.0 or 10 ng/mL TGF-b1 and
counted after 72 hours. Again, neutralizing anti-
bodies to TGF-b and FGF-2 inhibited TGF-b1–
induced proliferation, whereas an irrelevant
IgG had no effect. *P , 0.05 vs. control; **P ,
0.01 vs. control (Iscove’s medium 5 100%).
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Fig. 6. Effects of two tyrphostines on TGF-b–
induced proliferation in kidney fibroblasts.
Cells were plated at a density of 103 per well
and counted after 72 hours of stimulation with
TGF-b1 (1 ng/mL). Whereas the FGF-receptor
tyrosine kinase inhibitor tyrphostin AG1296 in-
hibited TGF-b1–induced proliferation in Tk 173
(A) and Tk 455 (B) kidney fibroblasts, no ef-
fect was seen with tyrphostin B42, which blocks
EGF receptor signal transduction. Cells grown
in Iscove’s medium alone served again as con-
trols. Neutralizing antibodies to TGF-b1 and
FGF-2 demonstrated the specificity of induced
proliferation. **P , 0.01 vs. control.
DISCUSSION lial, as well as tubular epithelial cells [4]. However, its
effects on fibroblast proliferation are largely unknown.Transforming growth factor-b1 plays an important
Our study demonstrates that TGF-b1 induces a robustrole in matrix accumulation in renal fibrogenesis [4]. The
delayed mitogenic response in medullary and corticalcytokine exists in three isoforms, of which TGF-b1 is
fibroblasts. Our results indicate that this effect is largelythe best studied [28]. TGF-b1 inhibits proliferation in
most cells, including glomerular epithelial and endothe- mediated via induction of FGF-2 synthesis and secretion,
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Fig. 7. Effects of a neutralizing antibody to
PDGF on TGF-b1–induced proliferation in
primary kidney and skin fibroblasts. Primary
cortical fibroblast lines Tk 458 (j) and Tk 467
(gray boxes) as well as primary skin fibroblast
lines Sk 448 ( ) and Sk 449 ( ) were sub-
jected to stimulation with TGF-b1 (1 ng/mL).
In addition, neutralizing antibodies to TGF-
b1, FGF-2, PDGF, or EGF were added. After
72 hours, bromodeoxyuridine incorporation
was determined. Unstimulated cells served as
controls (5 100%). Whereas the neutralizing
antibody to FGF-2 inhibited TGF-b1–induced
proliferation in cortical fibroblasts, only par-
tial inhibition was observed in skin fibroblasts.
Conversely, the neutralizing antibody to PDGF
prevented TGF-b1–induced proliferation in
skin fibroblasts but had only minor effects in
kidney fibroblasts. *P , 0.05 vs. control;
**P , 0.01 vs. control.
although additional effects may play a role as well. In Shankland et al, in mesangial cells, found that the prolif-
erative response to FGF-2 and PDGF was determinedaddition, we have shown that stimulation with TGF-b1
results in increased expression of cdk 2 and decreased mainly by down-regulated p27kip1 levels, although the
authors observed an up-regulation of cdk 2 as well [33].synthesis of p27kip1. Finally, we demonstrate that the pro-
mitogenic effect of TGF-b1 is not confined to renal fibro- In our study, p27kip1 expression was decreased by TGF-b1
up to 48 hours and returned to almost baseline after 72blasts but can be observed in skin fibroblasts as well.
However, PDGF may play a more important role in the hours, which may explain why DNA synthesis (as eval-
uated by bromodeoxyuridine incorporation) decreasesmediation of the mitogenic effects of TGF-b1 in skin
fibroblasts. thereafter. Conversely, expression of cdk 2 was robustly
increased up to 72 hours, demonstrating that TGF-b1–Despite its name, TGF-b1 leads to a growth arrest in
the G1 phase of the cell cycle in most cells. A special induced proliferation is caused by an up-regulation of
cdk 2 and a down-regulation of one of its inhibitors onfamily of protein kinases called the cdks regulate the
cell cycle [29]. These cdks associate with a group of the level of cell cycle-regulating proteins. Furthermore,
our results demonstrate that transformed and nontrans-proteins called cyclins, and only these dimers have the
necessary kinase activity to induce cell cycle progression. formed human kidney fibroblasts respond similarly to
TGF-b1, although the level of basal proliferation (andDuring the G1 phase, at least two cyclins form dimers
with their associated cdks: cyclin D/cdk 4 (or its homo- cdk 2 expression) was higher in transformed Tk 173
cells. This is of interest, since culture of primary renallogue cdk 6) and cyclin E/cdk 2 [29]. The kinase activity
of these cyclin/cdks complexes is inhibited by cdk inhibi- fibroblasts is cumbersome and loss of response to
TGF-b1 has been described after immortalization of ro-tors. p27kip1 is one of those inhibitors and is capable of
inhibiting cyclin D and cyclin E complexes, possibly by dent fibroblasts [34]. In addition, although we tested only
a limited number of cell lines, it shows that medullaryinteraction with the catalytic cleft for ATP. Antimito-
genic effects are mediated through an increase in cdk and cortical fibroblasts may react in a similar manner to
TGF-b1, and that there does not seem to be any majorinhibitors such as p27kip1. For example, the growth-inhibi-
tory effects of high glucose on mesangial cells are medi- difference in response if fibroblasts are derived from a
fibrotic or nonfibrotic kidney. However, we cannot ex-ated by TGF-b1 [30]. The effects of TGF-b1 in these
mesangial cells are characterized by increased expression clude the possibility that the in vitro conditions favor a
mitogenic response to TGF-b1.of the cdk inhibitor p27kip1 [31]. p27kip1 has been recently
proposed as a safeguard against inflammatory injury [32]. Our article is not the first to describe promitogenic ef-
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inhibits PDGF receptor tyrosine kinase activity. We there-
fore tested the effects of a neutralizing antibody to
PDGF and found only a modest effect in kidney fibro-
blasts. However, a considerable reduction of TGF-b1–
induced proliferation was notable in skin fibroblasts, fur-
ther corroborating the concept of fibroblast heterogeneity
[38]. In that regard, it will be interesting to study the in-
teractions between FGF-2 and connective tissue growth
factor (CTGF), which seems to mediate part of the ef-
fects of TGF-b1 on matrix synthesis [39].
Interactions between TGF-b1 and FGF-2 have been
described in the kidney before. Recently, Phillips et al
demonstrated that exposure of human proximal tubule
cells to TGF-b1 in a concentration of 10 ng/mL resulted
in an up to 1.5-fold increase in FGF-2 mRNA, which was
maximal after 24 hours and was paralleled by a time-
dependent increase in FGF-2 protein secretion [27]. More-
over, a recent study by Johnson et al demonstrated that
tubular epithelial cells secreted TGF-b1, which in turn
stimulated cell growth in human cortical fibroblasts [40].
Thus, our data corroborates data from the literature
that TGF-b1 induces a proliferative effect in organ fi-
broblasts and that this effect may be mediated by FGF-2.
However, our study is, to our knowledge, the first to
study the effects of TGF-b1 on medullary and cortical
fibroblasts and the first to neutralize systematically a
Fig. 8. Immunoblots for cdk 2 (A) and p27kip1 (B) in Tk 173 and Tk
variety of potentially involved cytokines. A simplified455 human kidney fibroblasts. Cells were stimulated with 1 ng/mL
TGF-b1 for 0, 24, 48, and 72 hours. Both cell lines displayed robust concept of the effects of TGF-b1 and FGF-2 on fibroblast
up-regulation of cdk 2 (33 kD) after 48 and 72 hours. Tk 173 cells had proliferation is depicted in Figure 9. What is the role
a much higher basal level of cdk 2 protein expression compared with
of proliferation in the process of renal scarring? Cellprimary Tk 455 fibroblasts. Conversely, levels of the cyclin-dependent
kinase inhibitor p27kip1 (27 kD) were similar at base line in both cell proliferation in general is believed to be central to the
lines and were decreased after 24 and 48 hours before returning to renal response to injury resulting in renal fibrosis [41].
basal levels after 72 hours.
Recently, Shankland et al demonstrated that two animal
models of chronic progressive renal disease had a more
progressive course in p27kip1 knockout mice with in-
creased glomerular and tubular cell proliferation [32].fects of TGF-b1 in cells of mesenchymal origin. As a
matter of fact, TGF-b was originally described as pro- Interstitial cell proliferation in human end-stage kidneys
was analyzed by Nadasdy et al. To their surprise, theymoting anchorage independent growth in normal rat kid-
ney fibroblasts in the presence of EGF [35]. Rosenbaum found that even scarred kidneys displayed high prolifera-
tive activity in tubuli and interstitial (noninflammatory)et al reported that TGF-b1 caused a dose- and time-
dependent induction of proliferation in human myofibro- cells [42]. Interstitial cell proliferation was also described
in models of interstitial fibrosis due to 5/6 nephrectomyblastic liver cells [36]. Similar to the results in our study,
that analysis described inhibition of this effect by addi- [43, 44]. Finally, we described recently a close correlation
between interstitial proliferation [determined by MIB-1tion of a neutralizing antibody to FGF-2. Although pro-
tein levels were not studied in that article, the group was (Ki-67) labeling] and interstitial FGF-2 staining [22].
In summary, our study has demonstrated that TGF-b1able to demonstrate an up-regulation in mRNA levels
for FGFR-1 and -2. Similar results were recently re- induces FGF-2 mRNA and protein synthesis in medul-
lary and cortical renal fibroblasts. This effect results inported for pulmonary fibroblasts in which TGF-b1 mark-
edly induced FGFR-1 and FGFR-2 [37]. Although we a delayed time- and partly dose-dependent mitogenic
response to TGF-b1 in kidney fibroblasts. Induction ofdid not study the expression of FGFRs in our study, we
were able to demonstrate that an inhibitor of the FGFR proliferation by TGF-b1 can be blocked almost com-
pletely by the addition of a neutralizing antibody totyrosine kinase prevented the mitogenic response to
TGF-b1, whereas an inhibitor of the EGF receptor tyro- FGF-2 in kidney but not in skin fibroblasts. The mito-
genic effects are paralleled by an increase in cdk 2 andsine kinase did not. However, the tyrphostin AG1296
not only blocks FGFR tyrosine kinase but additionally a decrease in p27kip1 syntheses. We conclude that the
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diaminetetraacetic acid; EGF, epidermal growth factor; EGTA, ethyl-
eneglycol tetraacid; ELISA, enzyme-linked immunosorbent assay; FCS,
fetal calf serum; FGF-2, basic fibroblast growth factor; FGFR, fibroblast
growth factor receptor; Ig, immunoglobulin; kD, kilodalton; LDH,
lactic acid dehydrogenase; PAS, periodic acid Schiff; PDGF, platelet-
derived growth factor; PTEC, proximal tubular epithelial cell; SEM,
standard error of the mean; TGF-b, transforming growth factor-b.
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